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Background: Antibacterial overuse, misuse and resistance have become a major global threat. The Joint Commission
International (JCI) accreditation standards include quality improvement and patient safety, which is exemplified by
antimicrobial stewardship. There are currently few reports on interventions to improve the quality of outpatient
antibacterial prescribing.
Methods: A before-after intervention study, aiming at antibacterial use in outpatients, was performed in a
university-affiliated hospital with 2.8 million outpatient visits annually during the journey to JCI accreditation
(March of 2012 - March of 2013). Comprehensive intervention measures included formulary adjustment, classification
management, motivational, information technological, educational and organizational measures. A defined daily dose
(DDD) methodology was applied. Pharmacoeconomic data and drug-related problems (DRPs) were statistically
compared between the two phases.
Results: The variety of antibacterials available in outpatient pharmacy decreased from 38 to 16. The proportion of
antibacterial prescriptions significantly decreased (12.7% versus 9.9%, P < 0.01). The proportion of prescriptions containing
the restricted antibacterials was 30.4% in the second phase, significantly lower than the value of 44.7% in the first phase
(P < 0.01). The overall proportion of oral versus all antibacterial prescriptions increased (94.0% to 100%, P < 0.01) when
measured as defined daily doses. Statistically significant increases in relative percentage of DDDs of oral antibacterials
(i.e., DDDs of individual oral antibacterial divided by the sum of DDDs of all antibacterials) were observed with
moxifloxacin, levofloxacin, cefuroxime axetil, ornidazole, clindamycin palmitate, cefaclor, amoxicillin and clarithromycin.
Occurrence rate of DRPs decreased from 13.6% to 4.0% (P < 0.01), with a larger decrease seen in surgical clinics
(surgical: 19.5% versus 5.6%; internal medicine: 8.4% versus 2.8%, P < 0.01). The total expenditure on antibacterials
for outpatients decreased by 34.7% and the intervention program saved about 6 million Chinese Yuan Renminbi
(CNY) annually.
Conclusion: The one-year intervention program on outpatient antibacterial use during the journey to JCI accreditation
reduced the expenditure on antibacterials, improved the appropriateness of antibacterial prescriptions. Quality
improvements need integrated multifaceted intervention measures and long-term adherence to the antibiotic
stewardship. Approach of i.v. to oral antibacterial switch, classification management, and motivational measures
may play the most efficient role in changing antibacterial prescription practices.
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Over use or the improper use of antibiotics can re-
sult in drug resistant bacteria as well as considerable
expense to health care system [1]. According to a new re-
port “Antibiotic Resistance Threats in the United States,
2013” issued by the U.S. Centers for Disease Control and
Prevention (CDC), antibiotic resistance in the United
States adds $20 billion in excess direct health care costs,
with additional costs to society for lost productivity as high
as $35 billion a year. The use of antibiotics is the single
most important factor leading to antibiotic resistance. Up
to 50 percent of all the antibiotics prescribed for people are
not needed or are not prescribed appropriately [2].
It is imperative to create a culture of safety and quality
within an organization that strives to continually im-
prove the quality of antibiotic prescribing. A systematic
review showed that antibiotic prescribing is a complex
process influenced by factors affecting all the actors in-
volved, including physicians, other healthcare providers,
healthcare system, patients and the general public [3].
Sumpradit et al. reported that prescription behavior
could be influenced by the factors like knowledge, atti-
tudes, subjective norms, peer pressure, patient expecta-
tions, drug promotion, physician’s diagnostic skill and
exposure to hospital formularies and standard thera-
peutic guidelines [4].
The benefits of antimicrobial stewardship have been
well described and implemented in the inpatient setting
[5-7]. Although studies of antimicrobial consumption in
outpatient services have been conducted in countries
like France, Jordan and the United States [8-10], there
are very few intervention programs specially targeting
the outpatient antibacterial use. A search of Medline be-
tween January 1 1993 and October 31 2013 revealed
only two intervention studies when using the keywords:
“antimicrobial stewardship and intervention and out-
patient and prescribing”. One study evaluated the effect
of clinician education coupled with audit and feedback
on broad-spectrum antibacterial prescribing for pediatric
outpatients with acute respiratory infections [11], and
the other study assessed the effect of a computerized
clinical decision support system (CDSS) on preventing
misuse of fluoroquinolone and azithromycin for acute
respiratory infections [12]. Compared with these inter-
ventions confined to special type of infection or particu-
lar class of antibiotics, multifaceted interventions for
quality improvement in outpatient antibiotic prescribing
has not been reported.
The fourth edition of Joint Commission International
(JCI) accreditation standard defined irrational drug use
as inappropriate drug, dose, frequency and route of ad-
ministration, real or potential drug-drug interactions
(DDIs), ignorance of allergy history, therapeutic duplica-
tions, and variation from organization criteria for use[13]. Rational antibacterial use is one of key measurable
elements in quality improvement required by JCI. The
Second Affiliated Hospital of Zhejiang University, School
of Medicine, Zhejiang University, China (SAHZU) suc-
cessfully passed the JCI accreditation as an academic
medical center hospital on Feb 24 of 2013. Rational anti-
bacterial use was listed as one of the nine patient safety
goals in SAHZU in 2012–2013. A working group com-
posed of infectious disease physicians, pharmacists, mi-
crobiologists, and administrators was established. This
group sought to implement multifaceted interventions at
the individual, organizational and policy levels to change
antibacterial prescription practices [4]. During the jour-
ney to JCI accreditation, the SAHZU group performed
an outpatient antibacterial stewardship intervention. The
aim of this article was to discuss the effectiveness of
such stewardship intervention in the outpatient setting and
provide some reference for international counterparts.
Methods
Data collection
A before-after intervention study, focusing on antibacterial
use in outpatient service was performed in SAHZU, a
2200-bed hospital with 2.8 million outpatient visits annu-
ally in Zhejiang Province, which has a population of ap-
proximately 54.4 million. The first phase was March of
2012 and the second phase was March of 2013. The study
was approved by Ethics Committee at SAHZU and it was
in compliance with the Helsinki Declaration.
Types of departments included in this study were
as follows: (1) Surgical clinics: Burn, Cardiovascular
Surgery, General Surgery Gynaecology, Neurosurgery,
Oral and Maxillofacial Surgery, Orthodontics, Ortho-
paedics, Otolaryngology, Plastic Surgery, Prosthodon-
tics, Surgical Oncology, Thoracic Surgery and Urology;
(2) Internal medicine clinics: Allergy and Clinical Immun-
ology, Cardiology, Dermatology, Endocrinology, Gastro-
enterology, Haematology, Infectious Diseases, Medical
Oncology, Nephrology, Neurology, Oral Medicine, Respira-
tory Medicine and Rheumatology.
The total number of prescriptions for outpatients and
total number of prescriptions containing antibacterials
(ATC code J01) were derived from the prescription
evaluation software embedded in the pharmacy manage-
ment information system. Antibacterial expenditure and
cost of all medications were calculated respectively. Herb
medicine prescriptions, compulsorily prescribed separ-
ately from western medicines in China, were excluded
when to calculate the total number of prescriptions
for outpatients. A subset of 5% of the antibacterial-
containing prescriptions was selected to evaluate for drug-
related problems (DRPs) through random sampling, and
was retrospectively evaluated by clinical pharmacists.
Antibacterial-associated DRPs included inappropriate drug
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route, use beyond approved indications, discordance be-
tween diagnosis and purpose of medication use, mis-
matches between antibacterial spectrum and the patient’s
infection, abuse of intravenous (i.v.) medications instead of
oral alternatives, ignorance of patient’s concomitant dis-
eased conditions and other miscellaneous problems.
Data on outpatient antibacterial use were collected
using the Anatomical Therapeutic Chemical (ATC)/
defined daily dose (DDD) method (WHO, version 2013)
[14,15]. Number of defined daily doses, also called DDDs,
was calculated as total dose consumed divided by DDD.
Relative percentage of DDDs of each oral antibacterial was
calculated as DDDs of individual oral antibacterial divided
by the sum of DDDs of all antibacterials. Daily expend-
iture is calculated as overall expenditure divided by DDDs.
Occurrence rate of DRPs was calculated as the number of
DRPs divided by the number of randomly selected anti-
bacterial prescriptions.
The data presented in the study is available in the ar-
chives of Drug & Therapeutics Committee (DTC) of
SAHZU. Access and use of these data need permission
from the SAHZU DTC.
Comprehensive intervention measures
Formulary adjustment & classification management
Antibacterials were classified as non-restricted (also
called “first line”), restricted (“second line”), or special-
grade (“third line”). Non-restricted antibacterials refer to
those with relatively low price, proven safety and clinical
efficacy and little effect on bacterial resistance. Re-
stricted antibacterials refer to those with proven safety
and clinical efficacy, but relatively high price and greater
impact on bacterial resistance. Special-grade antibacte-
rials are those with common or serious adverse reac-
tions, tendency of producing rapid bacterial resistance
or inadequate clinical efficacy and safety data. Each
grade of antibacterial matched corresponding prescrib-
ing privileges for physicians. The antibacterial formulary
was updated (Table 1). i.v. antibacterials were deleted
from the formulary of outpatient pharmacy. i.v. to oral
antibacterial switch therapy was encouraged in out-
patient services according to the principle of antimicro-
bial pharmacology (Table 2).
Motivational interventions
The director of each clinical department was asked to
sign a goal-setting responsibility plan for antibacterial
use with each director of clinical department. Reports of
prescription-related near misses were encouraged through
a voluntary online reporting system. Retrospective appro-
priateness evaluation of antibacterial-containing prescrip-
tions was performed monthly by clinical pharmacists and
the results were discussed in the meeting of the DTC andpublished on the hospital local area network. “Dear doctor”
letters were sent from the DTC to physicians. Physicians
were given the opportunity to present evidence and
argument against the results of audit-feedback during a
seven-day public notice period. Physicians who wrote in-
appropriate prescriptions would generally face a fine ac-
cording to the severity of the DRPs. The level of fine was
divided into three grades [low-grade: 100 Chinese Yuan
Renminbi (CNY); medium-grade: 200 CNY; high-grade:
300 CNY]. Prescribing privilege of the physician would
be revoked if there was a second instance of a high-grade
error.
Information technological interventions
Web-based prescription screening software and a CDSS
for antibacterial prescribing, embedded in electronic
medical records (EMRs), were implemented. Drug infor-
mation resources were updated, specifying maximum
dose, contraindications and special precautions. An im-
proved interface was created between the pharmacy
management information system for prescription audit-
ing which displayed both medication information (i.e.,
medication name, dose, administration route, dose fre-
quency and current medications) and patient’s key infor-
mation (e.g., patient name, identification number, age,
diagnosis, allergy history, body weight, body surface area,
nutrition status and clinical laboratory test results such
as hepatic and renal function, blood routine examination,
and serum drug levels).
Educational interventions
Physicians were instructed to follow the clinical guide-
lines. They also must record any real or potential aller-
gies or sensitivities in the electronic medical record for
outpatients and note the results of allergy skin tests
when prescribing special medications for outpatients.
Lectures were given, providing key opportunities for
physicians to learn about the topics of medication man-
agement therapy, DDIs, medication errors, adverse drug
reactions, therapeutic monitoring and typical cases of
irrational physician orders. Physicians and pharmacists
should receive specific training in antibacterial prescrip-
tion before they are granted different levels of prescrib-
ing or dispensing privileges.
Outcome measures
The outcome measures included proportion of prescrip-
tions containing antibacterials, proportion of prescrip-
tions containing non-restricted antibacterials, proportion
of prescriptions containing restricted antibacterials,
proportion of prescriptions containing special-grade
antibacterials, total expenditure on antibacterials for out-
patients, proportion of expenditure on antibacterials rela-
tive to all medications, proportion of expenditure on i.v.
Table 1 Formulary adjustment & classification management
First phase (March, 2012) Second phase (March, 2013)
Category Antibacterials Level Category Antibacterials Level
Macrolides Oral clarithromycin, Oral azithromycin,
Oral erythromycin, i.v. erythromycin




i.v. azithromycin 2 Cephalosporins
Cephalosporins The first generation Oral cephradine 1
The first generation Oral cephradine 1 The second generation Oral cefuroxime axetil,
Oral cefaclor
1
i.v. cefathiamidine 2 Oral cefprozi 2
The second generation Oral cefuroxime axetil, Oral cefaclor,
i.v. cefuroxime sodium
1 The third generation Oral cefdinir 2
Oral cefprozi, i.v. cefotiam 2 Fluoroquinolones Oral levofloxacin 1
The third generation Oral cefetamet pivoxil hydrochloride,
Oral cefdinir, i.v. ceftizoxime
2 Oral moxifloxacin 2
i.v. ceftriaxone sodium 1 Penicillins Oral amoxicillin 1







Monocyclic beta-lactam i.v. aztreonam 3 Nitroimidazoles Oral ornidazole 2
Fluoroquinolones Oral levofloxacin, i.v. levofloxacin,
i.v. ciprofloxacin
1 Tetracyclines Oral minocycline 1
Oral moxifloxacin, i.v. moxifloxacin 2 Lincosamides Oral clindamycin palmitate 1
Aminoglycosides i.v. etimicin 2 Miscellaneous Oral sulfamethoxazole/
trimethoprim
1
i.v. streptomycin sulfate 1
Penicillins i.v. benzylpenicillin sodium,
Oral amoxicillin
1
i.v. sulbenicillin sodium 2
Beta-lactam/beta-lactamase
inhibitor combinations






Nitroimidazoles Oral ornidazole, i.v. ornidazole 2
Tetracyclines Oral minocycline 1
Lincosamides Oral clindamycin palmitate,
i.v. clindamycin
1
Miscellaneous i.v. fosfomycin sodium 1
Notes: Level 1: non-restricted (also called “first line”) antibacterials; Level 2: restricted (“second line”) antibacterials; Level 3: special-grade (“third line”) antibacterials.
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of antibacterials, proportion of DDDs of all oral antibac-
terials relative to all antibacterials, relative percentage of
DDDs of each oral antibacterial, number of DRPs, occur-
rence rate of DRPs, occurrence rate of DRPs made by
surgeons, occurrence rate of DRPs made by internal
medicine physicians, occurrence rate of each DRP sub-
type and number of physicians who received fines during
the study period.
Statistical analysis
A descriptive analysis was performed. Pearson’s Chi-
square test was used for testing percentage differencesbetween two groups. Student’s t-test was used for stat-
istical comparisons between the means of two groups.
A P value < 0.05 was considered to be statistically sig-
nificant. A P value < 0.01 was considered to be highly
significant.
Results
General information and pharmacoeconomic data on
antibacterial prescriptions are presented in Table 3. Dur-
ing the first phase, average daily expenditure on i.v.
antibacterials was approximately 12 times that of oral an-
tibacterials [193.5 ± 172.2 CNY versus 16.1 ± 13.1 CNY,
P < 0.01]. The changes in relative percentage of DDDs of
Table 2 Approach of i.v. to oral antibacterial switch therapy
i.v. antibacterials Oral antibacterials Daily expenditure
ratio (oral to i.v.)
Fluoroquinolones
i.v. moxifloxacin Moxifloxacin tablets 0.10
i.v. levofloxacin Levofloxacin tablets 0.13
Cephalosporins
The first generation







i.v. cefotiam Cefaclor capsules 0.092
i.v. cefuroxime sodium Cefaclor SR tablets 0.99
Cefprozi tablets 0.15
Cefuroxime axetil tablets 0.061
The third generation
i.v. ceftizoxime sodium Cefdinir capsules 0.35
i.v. ceftriaxone sodium Cefetamet pivoxil tablets 0.042
Macrolides
i.v. azithromycin Azithromycin tablets 0.29
Roxithromycin tablets 0.13
Clarithromycin SR tablets 0.088
Clarithromycin tablets 0.21
Aminoglycosides
i.v. etimicin Levofloxacin tablets 0.097
Cefdinir capsules 0.34
Cefetamet pivoxil tablets 0.090
Nitroimidazoles
i.v. ornidazole Ornidazole tablets 0.017
Lincosamide
i.v. clindamycin Clindamycin palmitate
tablets
1.11
Daily expenditure was expressed in Chinese Yuan Renminbi (CNY); i.v.: intravenous;
SR: sustained release. Daily expenditure ratio (oral to i.v.) was calculated as daily
expenditure of oral antibacterial divided by daily expenditure of the corresponding
i.v. antibacterial.
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Table 4. Statistically significant increases in relative per-
centage of DDDs of oral antibacterials were observed
with moxifloxacin, levofloxacin, cefuroxime axetil, orni-
dazole, clindamycin palmitate, cefaclor, amoxicillin and
clarithromycin. Cefaclor demonstrated the largest in-
crease in utilization. Cefuroxime axetil was the most usu-
ally prescribed antibacterials during each phase. The total
expenditure for outpatient antibacterials decreased by
34.7% and the intervention program saved 0.51 million
CNY per month. It is estimated to save about 6 million
CNY annually.DRPs derived from randomly selected antibacterial
prescriptions for outpatients are listed in Table 5. The
proportion of injectable antibacterials prescribed dra-
matically decreased from 15.6% in the first phase to
0.2% in the second phase (P < 0.01). The occurrence rate
of DRPs decreased from 13.6% in the first phase to 4.0% in
the second phase (P < 0.01). In the first phase, surgeons
demonstrated a significantly higher DRP rate than internal
medicine physicians (19.5% versus 8.4%, P < 0.01); how-
ever, this difference was not seen in the second phase.
Overall rates of DRPs decreased for both internal medi-
cine physicians and surgeons when comparing the first
and second phases (surgeons: 19.5% versus 5.6%; internal
medicine physicians: 8.4% versus 2.8%, P < 0.01). The
magnitude of decrease in occurrence of DRPs was
more profound in surgeons. Significant differences be-
tween two phases were also observed with inappropriate
co-medication with other antibacterials, mismatches be-
tween antibacterial spectrum and the patient’s infection,
and abuse of i.v. medications instead of oral alternatives
(P < 0.01).
During the study period, sixty-one physicians were
fined due to inappropriate prescribing. One surgeon
received a fine of 13000 CNY at a monthly DTC meeting
following audit-feedback. The inappropriateness of antibi-
otics prescribed by this surgeon was reflected in im-
proper combination antibiotic treatment (19 prescriptions),
lack of clear clinical features of infection plus im-
proper combination antibiotic treatment (26 prescriptions),
off-label use (2 prescriptions), inappropriate antibiotic
choice (1 prescription), and inappropriate antibiotic
choice plus improper combination antibiotic treatment
(3 prescriptions). For example, he prescribed isepamicin
sulfate-levofloxacin combination for a patient with en-
larged axillary lymph nodes in the right axillary region,
ceftizoxime-levofloxacin combination for treatment of
lower extremity infection, and cefotiam-isepamicin sulfate-
ornidazole combination for patient with acute appendicitis.
Discussion
The significant decrease in the proportion of antibacter-
ial prescriptions was an interesting outcome, as out-
patient turnover and total number of prescriptions for
outpatients did not decrease between the two phases.
The increased proportion of prescriptions containing
non-restricted antibacterials and the decreased propor-
tion of prescriptions containing restricted antibacterials
indicated that the stewardship efforts were successful.
The i.v.-to-oral switch therapy may reduce length of
hospital stay, healthcare costs and risk of complications
related to i.v. access [16,17]. For outpatients, oral moxi-
floxacin is a superior choice versus the i.v. formulation,
with the advantages including one-tenth of the daily ex-
penditure of i.v. medication, convenient administration
Table 3 General information and pharmacoeconomic data on antibacterial prescriptions
Indicators First phase Second phase
(March, 2012) (March, 2013)
Kinds of antibacterials in outpatient pharmacy 38 16
Kinds of the third line antibacterials 1 0
Kinds of the second line antibacterials 17 4
Kinds of the first line antibacterials 20 12
Kinds of i.v. antibacterials 22 0
Kinds of oral antibacterials 16 16
Total number of prescriptions for outpatients 88425 90459
Total number of prescriptions containing antibacterials 11194 8920
Proportion of prescriptions containing antibacterials# 12.7% 9.9%
Proportion of prescriptions containing non-restricted antibacterials# 55.1% 69.6%
Proportion of prescriptions containing restricted antibacterials# 44.7% 30.4%
Proportion of prescriptions containing special-grade antibacterials# 0.14% 0
Total expenditure on antibacterials for outpatients (million CNY) 1.4760 0.9644
Proportion of expenditure on antibacterials relative to all medications 6.9% 4.1%
Proportion of expenditure on i.v. antibacterials relative to all antibacterials 30.5% 0
Sum of DDDs of antibacterials for outpatients 65930 61403
Proportion of DDDs of oral antibacterials for outpatients relative to all antibacterials# 94.0% 100%
Notes: #P < 0.01 (first phase vs second phase). Differences between the two phases were tested for statistical significance using Pearson’s Chi-square test. A P value < 0.05
was considered to be statistically significant. A P value < 0.01 was considered to be highly significant. CNY: Chinese Yuan Renminbi. DDDs: number of defined daily doses
(total dose consumed/defined daily dose). Daily expenditure = overall expenditure/DDDs.
Table 4 Comparison in relative percentage of DDDs of
oral antibacterials before and after intervention





Cefuroxime axetil tablets# 10.6% 13.2%
Levofloxacin tablets# 9.6% 12.6%
Moxifloxacin tablets# 8.6% 9.1%
Amoxicillin# 8.1% 11.4%
Cefdinir capsules 7.0% 7.2%
Clarithromycin tablets# 5.7% 7.4%
Cefradine capsules# 3.1% 1.8%
Ornidazole tablets# 2.3% 2.8%
Cefaclor SR tablets & Cefaclor capsules# 1.8% 9.3%
Cefprozi tablets# 1.72% 1.2%
Clindamycin palmitate tablets# 0.48% 1.2%
Notes: #P < 0.01 (first phase vs second phase). Differences between the two
phases were tested for statistical significance using Pearson’s Chi-square test.
A P value < 0.01 was considered to be highly significant. DDDs: number of of
defined daily doses (total dose consumed/defined daily dose). Relative percentage
of DDDs: DDDs of individual antibacterial divided by the sum of DDDs of all
antibacterials. SR: sustained release.
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90-min intravenous drip), lower occurrence rate of
infusion-related side effects (e.g., thrombophlebitis),
and omission of additional non-drug cost associated with
infusion therapy (e.g., clinical work load, hospital waste
and administration cost such as needles, syringes, dress-
ings, antiseptics and administration set). Oral levofloxa-
cin and ornidazole have near 100 percent bioavailability;
therefore a comparable exposure to the i.v. regimen may
be achieved after oral administration [18,19]. i.v. to oral
switch programme for clindamycin and cefuroxime
have been also proved with great economic advantages
[20,21]. Clinicians should consider oral antibacterials as
soon as possible for outpatients who need infection con-
trol. The DDDs value represents the tendency of drug use,
with higher DDDs indicating more frequent utilization
[22]. Sum of DDDs of antibacterials for outpatients in the
second phase was lower than that in the first phase (61403
versus 65930). Moreover, in this program, statistically sig-
nificant changes of proportion of DDDs of eight oral anti-
bacterials between two phases indicated that i.v. to oral
switch therapy approach was basically successful. A de-
crease in the relative percentage of DDDs for cefprozi tab-
lets may have been due to the introduction of cefaclor
sustained release formulation into SAHZU in July, 2012.
A decrease in the relative percentage of DDDs for cefra-
dine capsules may have been in part due to increased
Table 5 Drug-related problems derived from randomly selected antibacterial prescriptions for outpatients
Indicators First phase Second phase
(March, 2012) (March, 2013)
Number of randomly selected antibacterial prescriptions for outpatients* 559 446
Number of DRPs 76 18
Occurrence rate of DRPS# 13.6% 4.0%
Occurrence rate of DRPs made by surgeonsΔ# 19.5% 5.6%
Occurrence rate of DRPs made by internal medicine physicians# 8.4% 2.8%
Occurrence rate of each subtype of DRP
(1) Inappropriate coadministration with non-antibacterials 4 (0.7%) 6 (1.3%)
(2) Inappropriate co-medication with other antibacterials# 17 (3.0%) 3 (0.7%)
(3) Inappropriate dosing frequency 8 (1.4%) 3 (0.7%)
(4) Inappropriate dose 1 (0.2%) 2 (0.4%)
(5) Inappropriate administration route 1 (0.2%) 0
(6) Use beyond approved indications 1 (0.2%) 2 (0.4%)
(7) Discordance between diagnosis and purpose of medication use 8 (1.4%) 2 (0.4%)
(8) Mismatches between antibacterial spectrum and the patient’s infection# 15 (2.7%) 0
(9) Abuse of i.v. medications instead of oral alternatives# 16 (2.9%) 0
(10) No diluent for i.v. antibacterials 1 (0.2%) 0
(11) Ignorance of patient’s other diseases 4 (0.7%) 0
Notes: #P < 0.01 (first phase vs second phase). ΔP < 0.01 (surgeons vs internal medicine physicians). Differences between two groups were tested for statistical
significance using Pearson’s Chi-square test. A P value < 0.05 was considered to be statistically significant. A P value < 0.01 was considered to be highly significant.
DRPs: drug-related problems.
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among physicians and pharmacists.
Occurrence rates of DRPs between surgical clinics and
internal medicine clinics exhibited significant difference
in the first phase, but not in the second phase, indicating
that surgeons were previously less likely to appropriately
prescribe outpatient antimicrobials than internal medi-
cine physicians; however, upon intervention, surgeon
prescribing practices improved greatly. A systematic
review revealed that physicians’ attitudes were the most
influential intrinsic factor influencing antibacterial pre-
scribing and healthcare system-related factors like time
pressure and corresponding policies/guidelines imple-
mented were the most common extrinsic factors [23]. A
substantial number of surgeons were found to have sub-
optimal knowledge about antibacterial use and prescrib-
ing habits in the first phase. Besides of continuing
education and training directed to them, fines were im-
posed on physicians who refused to mend their ways
after repeated education. Furthermore, the outpatient
service environment and treatment process were further
improved. Such strenuous efforts improved the quality
of antibacterial prescribing.
DRPs associated with “use beyond approved indications”
were identified. Moxifloxacin tablet was prescribed for
treatment of urinary tract infection in a prescription. How-
ever, package insert of moxifloxacin tablet specifies that theformulation is only indicated for the treatment of adults
(≥ 18 years of age) with infections caused by susceptible
isolates of the designated microorganisms in the condi-
tions listed below: acute bacterial sinusitis, acute bacterial
exacerbation of chronic bronchitis, community acquired
pneumonia, uncomplicated skin and skin structure infec-
tions and complicated intra-abdominal infections. Not all
fluoroquinolones can be used for urinary tract infections
based on their pharmacokinetic profiles [24]. Treatment
of infections in the urine is a common misuse of moxiflox-
acin, and clinicians should be careful about use of this
agent for these infections since moxifloxacin achieves con-
siderably lower concentrations in the urine than other
fluoroquinolones and it is not approved for this indication.
This study showed that the use of 0.4% of antibacterial
prescriptions in the second phase was still beyond ap-
proved indications. Although off-label manner of prescrib-
ing cannot always be avoided, physicians should only use
unapproved drugs in cases when suitable alternatives are
unavailable and there are scientific evidence regarding
safety and effectiveness [25,26].
The incidence of DRPs such as bug-drug mismatches
and abuse of i.v. medications rather than highly bioavail-
able oral alternatives were successfully reduced in the
second phase (P<0.01). In the first phase, sulbenicillin, a
penicillin antibiotic active against P. aeruginosa, was se-
verely misused for treatment of infections which were
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sulbenicillin was prescribed for outpatients who got
tooth extraction. Finally, the DTC eliminated sulbenicil-
lin from the antibiotic formulary for outpatient clinical
practice. Special trainings sessions were directed toward
dentists to prevent the overuse and misuse of antibacte-
rials, which was successful.
With regard to the indicator “Inappropriate coadmin-
istration with non-antibacterials”, no obvious improve-
ment was observed. In China, antibacterials could be
prescribed with other western medicines in the same
prescription sheet. Coadministration of antibacterials
and probiotics were observed in both phases. Spaced
dosing was not specified when physicians wrote pre-
scriptions. Since probiotics contain live microorganisms,
concurrent administration of antibacterials could kill a
large number of the organisms, reducing the efficacy of
the Lactobacillus and Bifidobacterium species. However,
all of patients in the two phases were instructed by phar-
macists to separate administration of antibacterials from
these bacteria-derived probiotics by at least two hours.
Although a significant reduction in occurrence of
DRPs was observed after the intervention program, there
still were 18 DRPs in the second phase. It indicated of
further opportunities for improvement. In theory, the
appropriateness of all prescriptions should be audited by
pharmacists. In SAHZU, prospective prescription audit
is a routine pharmaceutical service for inpatients. How-
ever, outpatient pharmacy has not yet established such
working process due to big workload (5000 prescriptions
each day). This hasn’t been possible, due to the relatively
insufficient personnel and the particularity of outpatient
service medical treatment in comparison with inpatient
service (about 10000 outpatients each day versus 2200
inpatients each day). In Mainland of China, there is
hardly any hospital which practices prospective prescrip-
tion audit promptly in outpatient service when physi-
cians prescribe via electronic prescribing system. Some
large hospitals in China take the following measures:
(1) Install online prescription screening software em-
bedded in electronic prescribing system and pharmacy
administration system, allowing severe DRPs to be auto-
matically intercepted when physicians are prescribing.
(2) Pharmacists will contact the corresponding physi-
cians if they detect DRPs when outpatients hand over
the prescriptions to pharmacists. Such interventions
bring potential problems, and are likely to cause the
tension between the hospital and patients (i.e., a patient
would be reluctant to go back to the physician’s clinic
for prescription revision because it will be perceived as
a waste of time, and the physician’s professional image
might be damaged).
Suboptimal prescribing habits involving antibiotics
in China is partly associated with economic incentives,driven by non-standardized drug-promotions by pharma-
ceutical companies. However, many medical disputes be-
tween patients and hospitals are associated with irrational
drug use. Therefore, education is an essential element of
an intervention program designed to influence prescribing
behavior and can provide a knowledge basis that will en-
hance the acceptance of stewardship strategies. Communi-
cation is also important among physicians, pharmacists
and administrators before initiating intervention programs.
Consideration should be given to all staff involved (i.e.,
values, personality, perceptions, emotions and ability). The
working mode of the DTC on outpatient antibacterial
stewardship intervention, especially allowing physicians to
present evidence and argument to the results of audit-
feedback during a seven-day public notice period, was piv-
otal to the willing acceptance of punishment by physicians
who made severe DRPs. Rational antibiotic use, to a certain
extent, is a health administration issue more so than a pro-
fessional issue.
A literature review of clinical and economic outcomes
of pharmaceutical services related to antibacterial use
showed that the most frequently observed outcomes
with a positive impact were appropriateness of prescrib-
ing and cost savings [27]. Although the study in SAHZU
showed some positive outcomes, it had some limitations
which were shown as follows: (1) Follow-up of outpatients’
therapeutic outcome was not conducted; (2) Patient
adherence to treatment regimens were not monitored so
that prescribing data may not accurately represent actual
antibacterial consumption); (3) Multiple comparisons for
the same dataset might increase type I error in showing
the impact of interventions, and for these kind of studies
interrupted time-series analysis would be more reliable
method [28].
Conclusion
The effects of an outpatient antibacterial stewardship
intervention were examined in an academic medical
center hospital during the journey to JCI accreditation.
The intervention program reduced the expenditure on
antibacterials, improved the appropriateness of antibac-
terial prescriptions. Quality improvements need con-
tinuous efforts, integrated multifaceted intervention
measures and long-term adherence to the antibiotic
stewardship. Approach of i.v. to oral antibacterial switch
therapy, classification management, and motivational mea-
sures may play the most direct and efficient role in chan-
ging antibacterial prescription practices.
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